PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN VERSUS PEGINTERFERON ALPHA-2B PLUS RIBAVIRIN IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS OF A PROSPECTIVE RANDOMISED TRIAL

1
PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN VERSUS
PEGINTERFERON ALPHA-2B PLUS RIBAVIRIN IN NAIVE
PATIENTS WITH CHRONIC HEPATITIS C VIRUS
INFECTION RESULTS OF A PROSPECTIVE RANDOMISED
TRIAL
Ascoine et.al
EASL 2008 - Update
2
Ascione et al investigator-initiated,
randomized, controlled study
PEG-INF a-2b 1.5 µg/kg plus RBV 1000/1200 mg
Follow-up
CHC, naïve,all G, n320
PEGASYS 180 µg plus RBV 1000/1200 mg
Follow-up
Study Weeks
0
24/48
48/72
Randomization (11)
G1/4 was treated for 48 weeks, G2/3 was
treated for 24 weeks
Ascione et al, EASL 2008, late-breaker, oral
3
Ascione et al Results (ITT)
p0.008
p0.04
p0.046
26
37
18
Ascione et al, EASL 2008, late-breaker, oral
4
Ascione et al - Results (ITT)
p0.0009
p0.7
26
35
Ascione et al, EASL 2008, late-breaker, oral
5
Ascione et al Results (ITT)
26
49
Ascione et al, EASL 2008, late-breaker, oral
6
Ascione et al Results and Conclusion

• Results
• At multivariate analysis the variables
  independently associated with SVR were male sex
  absence of cirrhosis G2/3 treatment with
  PEGASYS
• Side effects were similar, although there were
  more withdrawals for side effects in the group
  treated with PEG-INF a-2b.

Ascione et al, EASL 2008, late-breaker, oral
7
Conclusions

• Pegasys has been shown to be superior over
  PEG-INF alfa-2b in a high standard comparative
  study
• Pegasys has been shown to be superior in the
  broadest range of patients
• All genotypes (1-4)
• Majority of patients (non-cirrhotic)
• High viral load (gt500,000 IU)

8
?????. ???? ??????

• ????? ????? ??????